Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
1.545    -0.165 (-9.65%)
Bid:
1.215
Ask:
1.62
Spread: 0.405 (33.333%)
Market Cap: £1.59m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Exercise of Options, Equity Issue, Director/PDMR

29 Oct 2021 13:24

RNS Number : 7683Q
Litigation Capital Management Ltd
29 October 2021
 

29 October 2021

Litigation Capital Management Limited

("LCM" or the "Company")

Exercise of Options, Issue of Equity, Director / PDMR Shareholding

Litigation Capital Management Limited (AIM:LIT), a leading international alternate asset manager of disputes financing solutions, announces:

Executive CEO

On 27 October 2021 Patrick Moloney, Chief Executive Officer of the Company exercised 900,000 options (the "Executive Options") at an exercise price of A$1.00. The Company has agreed to issue and allot in total 900,000 new Ordinary Shares ("Ordinary Shares") in the capital of the Company to Patrick Moloney. Following Admission, Patrick Moloney will hold 10,153,258 shares and 8.55% of the issued share capital.

The LCM Loan Share Plan ("LSP") will be utilised to pay the strike price.

Non-Executive Directors

On 27 October 2021 Seistend Pty Ltd, an entity associated with Dr David King, a non-executive director of the Company, exercised 600,000 options (the "Non-Executive Options") at an exercise price of A$1.00. The Company has agreed to issue and allot in total 600,000 new Ordinary Shares in the capital of the Company.

The Executive Options and the Non-Executive Options were granted on 21 September 2016.

The Company has made an application for the 1,500,000 Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective on 5 November 2021.

Concurrently with the exercise, Seistend Pty Ltd, an entity associated with Dr David King sold 250,000 Ordinary Shares to Jonathan Moulds, Chairman of the Company, at a price of GBP £1.00.

Following Admission, Seistend Pty Ltd, an entity associated with Dr David King, and Jonathan Moulds will hold 1,951,484 and 250,000 Ordinary Shares respectively, and 1.64% and 0.21% of the Company's 118,699,145 Ordinary Shares in issue, each with voting rights.

This figure of 118,699,145 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company does not hold any Ordinary Shares in Treasury.

Enquiries

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

 

 

Alma PR

Tel: 020 3405 0205

Justine James

Kieran Breheny

Molly Gretton

LCM@almapr.co.uk

 

 

 

NOTES TO EDITORS

Litigation Capital Management (LCM) is an alternate asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

www.lcmfinance.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Seistend Pty Ltd, an entity associated with Dr David King

2.

Reason for the notification

a)

Position / status

Non-Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Exercise of Options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

A$1.00

600,000

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Seistend Pty Ltd, an entity associated with Dr David King

2.

Reason for the notification

a)

Position / status

Non-Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Sell of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£1.00

250,000

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Jonathan Moulds

2.

Reason for the notification

a)

Position / status

Chairman

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£1.00

250,000

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Patrick John Moloney

2.

Reason for the notification

a)

Position / status

Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Interest in Ordinary Shares under a Loan Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$1.00

900,000

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPGUPUUPGGPB
Date   Source Headline
30th Jun 20267:00 amRNSCovenant Waiver Extension
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.